Key Highlights for Investors

• Potential Disposal: China Resources Pharmaceutical Investment Company Limited (CR Pharmaceutical Investment), a wholly-owned subsidiary of China Resources Pharmaceutical Group Limited (the “Company”), is considering disposing of approximately 5.88% equity interests in Tianmai Biotechnology Development Co., Ltd. (“Tianmai Biotechnology”).
• Public Tender Process: The disposal will be conducted through a public tender on the Shanghai United Assets and Equity Exchange at an initial minimum listing price of about RMB 0.51 billion.
• Equity Position: As of the announcement date, CR Pharmaceutical Investment and its subsidiary collectively hold approximately 23.75% equity interests in Tianmai Biotechnology.
• Independence from Previous Disposal: This potential disposal is independent from a previous disposal of certain equity interests in Tianmai Biotechnology, which was announced on 9 February 2026.

Details and Implications

The board of China Resources Pharmaceutical Group Limited has informed investors that the disposal plan is still at a preliminary stage. As of now, no intended transferee has been identified and no definitive transaction agreements have been signed. The potential transaction is subject to various factors, including:

• Successful completion of the public tender process.
• Execution of relevant agreements and conditions as stipulated in the tender.

If an intended transferee is identified, CR Pharmaceutical Investment will proceed to sign the necessary transaction agreements. However, if no transferee emerges, the public tender process will automatically lapse and terminate.

The company has stated that it will comply with the relevant requirements under Chapter 14 of the Listing Rules, should any transaction agreement be executed.

Investor Guidance and Potential Impact

• Price Sensitivity: The announcement is considered inside information and may be price sensitive, as it involves a significant potential transaction for a notable subsidiary holding.
• Shareholder Action: Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities, as the outcome of the tender process and any resulting transaction could impact the Company’s financial standing and market value.
• Uncertainty: The disposal is not guaranteed and is dependent on market response to the public tender. There is a risk that no buyer will be found and the process may lapse.

Board of Directors

As of the date of the announcement, the board comprises a mix of executive, non-executive, and independent non-executive directors, led by Chairman Mr. Bai Xiaosong.

Conclusion

The proposed disposal of equity in Tianmai Biotechnology marks a potential strategic shift for China Resources Pharmaceutical Group Limited. Due to the size of the transaction (approximately RMB 0.51 billion for a 5.88% stake), the outcome of the public tender process, and the potential impact on the Company’s financials and shareholding structure, this development is significant and could influence the Company’s share price. Investors should monitor future announcements closely.